NPI: 1881997831 · SPOKANE, WA 99208 · Family Medicine Physician · NPI assigned 12/14/2010
Authorized official WILSON, AARON controls 20+ related entities in our dataset. Read more
| Authorized Official | WILSON, AARON (CEO) |
| NPI Enumeration Date | 12/14/2010 |
Other providers sharing the same authorized official: WILSON, AARON
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 18,358 | $564K |
| 2019 | 25,049 | $983K |
| 2020 | 19,548 | $724K |
| 2021 | 25,617 | $853K |
| 2022 | 22,514 | $958K |
| 2023 | 34,937 | $914K |
| 2024 | 21,910 | $435K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 70,949 | 69,340 | $3.31M |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14,802 | 14,486 | $879K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3,868 | 3,817 | $327K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3,766 | 3,727 | $155K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 4,639 | 4,556 | $151K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2,750 | 2,719 | $140K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 5,191 | 5,060 | $110K |
| G0467 | Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 3,440 | 3,119 | $96K |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1,181 | 1,171 | $86K |
| T1015 | Clinic visit/encounter, all-inclusive | 257 | 251 | $48K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3,335 | 3,295 | $43K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 870 | 853 | $27K |
| 81025 | 1,796 | 1,750 | $13K | |
| 87634 | 202 | 197 | $12K | |
| 81003 | 6,267 | 6,135 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,041 | 1,012 | $10K |
| 71046 | Radiologic examination, chest; 2 views | 620 | 607 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 326 | 314 | $3K |
| 36415 | Collection of venous blood by venipuncture | 748 | 731 | $3K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 17 | 17 | $2K |
| 87210 | 68 | 67 | $282.70 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 2,141 | 2,066 | $34.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 38 | 37 | $29.20 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 26 | 26 | $16.87 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 31 | 31 | $4.12 |
| 1159F | 4,767 | 4,727 | $0.00 | |
| 3078F | 5,700 | 5,649 | $0.00 | |
| 3077F | 61 | 59 | $0.00 | |
| 3008F | 17,365 | 17,016 | $0.00 | |
| 3079F | 1,747 | 1,731 | $0.00 | |
| 1034F | 1,713 | 1,689 | $0.00 | |
| 3080F | 24 | 24 | $0.00 | |
| 1035F | 455 | 451 | $0.00 | |
| 3074F | 7,468 | 7,400 | $0.00 | |
| 3075F | 264 | 262 | $0.00 |